Adaptive Biotechnologies (ADPT)
(Delayed Data from NSDQ)
$10.33 USD
+0.09 (0.88%)
Updated Aug 1, 2025 04:00 PM ET
After-Market: $10.45 +0.12 (1.16%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth D Momentum F VGM
Fundamental Charts
About Market Cap
As of the previous market close, Adaptive Biotechnologies Corporation has a market cap of $1.56B, which represents its share price of $10.24 multiplied by its outstanding shares number of 151.92M. As a small-cap company, ADPT's shareholders are generally exposed to more risk than shareholders of mid and large-cap companies.
The company's Market Capitalization is a measurement of company size. It is calculation of the company's share price times the number of outstanding shares. Large market cap companies give stability and are good long-term investments. Small market cap companies can produce faster growth and bigger returns, but their stockholders are exposed to more risk.
ADPT 10.33 +0.09(0.88%)
Will ADPT be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for ADPT based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ADPT
Moderna (MRNA) Reports Q2 Loss, Beats Revenue Estimates
Are Medical Stocks Lagging Adaptive Biotechnologies (ADPT) This Year?
ADPT: What are Zacks experts saying now?
Zacks Private Portfolio Services
Adaptive Biotechnologies (ADPT) Surges 12.5%: Is This an Indication of Further Gains?
What Makes Adaptive Biotechnologies (ADPT) a New Buy Stock
Is Adaptive Biotechnologies (ADPT) Stock Outpacing Its Medical Peers This Year?
Other News for ADPT
COIN, BMNR, RBLX: Cathie Wood Buys Over $54M of Crypto Stocks, Dumps Roblox Stake
Adaptive Biotechnologies price target raised by $2 at BTIG, here's why
BTIG Increases Price Target for Adaptive Biotechnologies (ADPT) to $13
Aristotle Large Cap Growth Q2 2025 Commentary
Cathie Wood's Ark Invest Loads Up On Absci, Offloads CRISPR Therapeutics